Previous 10 |
home / stock / onppf / onppf news
Number of shares and votes in Oncopeptides PR Newswire STOCKHOLM , March 31, 2021 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the ...
Oncopeptides AB (ONPPF) announces that PEPAXTO (melphalan flufenamide) has been added to the Multiple Myeloma Clinical Practice Guidelines of the National Comprehensive Cancer Network ((NCCN)) in Oncology.PEPAXTO, in combination with dexamethasone, was granted accelerated appro...
Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO® PR Newswire STOCKHOLM , March 15, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the developmen...
Oncopeptides AB (ONPPF) announced that its multiple myeloma treatment PEPAXTO (melphalan flufenamide) is now commercially available and that the first patients are being treated with the drug.PEPAXTO, in combination with dexamethasone, was granted accelerated approval by the FDA las...
Oncopeptides AB (ONPPF): Q4 GAAP EPS of -SEK7.59.Cash and cash equivalents of SEK840.3MPress Release For further details see: Oncopeptides AB reports Q4 results
News, Short Squeeze, Breakout and More Instantly...
Oncopeptides Company Name:
ONPPF Stock Symbol:
OTCMKTS Market:
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto PR Newswire STOCKHOLM , July 20, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on resear...
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time PR Newswire STOCKHOLM , Jan. 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and deve...
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting PR Newswire STOCKHOLM , Sept. 11, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat he...